Chapter title |
Remaining Challenges in the Treatment of Tyrosinemia from the Clinician’s Viewpoint
|
---|---|
Chapter number | 19 |
Book title |
Hereditary Tyrosinemia
|
Published in |
Advances in experimental medicine and biology, January 2017
|
DOI | 10.1007/978-3-319-55780-9_19 |
Pubmed ID | |
Book ISBNs |
978-3-31-955779-3, 978-3-31-955780-9
|
Authors |
Grant A. Mitchell, Hao Yang |
Abstract |
This chapter provides a clinical perspective on the challenges that stand between current clinical practice and a cure for hepatorenal tyrosinemia (HT1). HT1 has been transformed in the last 50 years from an aggressive often undiagnosed childhood disease causing liver failure or liver cancer, with infant death in most patients, to a condition that is detectable at birth, and for which treatment with nitisinone (NTBC) and diet can prevent detectable liver or kidney abnormalities. What challenges remain? The properties of the affected metabolic pathway and the broad spectrum of severity seen in untreated patients are incompletely understood but potentially important for patients. Available treatments have potential complications, including liver transplantation (risks of surgery and of immunosuppression to prevent rejection), nitisinone and diet therapy (hypertyrosinemia, corneal opacities, nutritional imbalances and possibly developmental delay). The detection of liver cancer is imperfect and laborious. The effects of tyrosinemia during pregnancy are little-known. Although animal models of HT1 are becoming standard research tools in cell replacement and gene modification therapy, these techniques are not currently applicable to HT1 itself. Treatment adherence is variable, causing concern about long term outcome for some patients. Around the world, there are great disparities in the diagnosis and treatment of HT1. Most affected individuals are born in places where newborn screening for HT1 is not performed and where appropriate treatment is not available. We hope that this list will help to focus on some of these remaining obstacles to a cure for HT1. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 37 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 16% |
Student > Ph. D. Student | 6 | 16% |
Student > Bachelor | 5 | 14% |
Student > Postgraduate | 3 | 8% |
Student > Doctoral Student | 2 | 5% |
Other | 4 | 11% |
Unknown | 11 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 14% |
Biochemistry, Genetics and Molecular Biology | 3 | 8% |
Nursing and Health Professions | 3 | 8% |
Psychology | 3 | 8% |
Other | 3 | 8% |
Unknown | 13 | 35% |